ヒト用インスリンの世界市場：糖尿病患者の増加に伴い、市場は拡大基調に

当レポートでは、世界のヒト用インスリン市場について調査し、タイプ別、疾患別、ブランド別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

第2章 市場の要約

第3章 ポーターのファイブフォース分析

第4章 業界概要

• 市場の定義
• 市場促進要因
• 市場促進要因の影響分析
• 市場抑制要因
• 市場抑制要因の影響分析
• 市場動向

第5章 世界市場規模と予測

第6章 市場規模と予測： タイプ別

• 従来型ヒト用インスリン
• 現代型ヒト用インスリン

第7章 従来型ヒト用インスリンの市場規模と予測：タイプ別

• 短時間作用型ヒト用インスリン
• 中間型ヒト用インスリン
• プレミクスヒト用インスリン

第8章 現代型ヒト用インスリンの市場規模と予測：タイプ別

• 速効型ヒト用インスリン
• 持続型ヒト用インスリン
• プレミクスヒト用インスリン

第9章 市場規模と予測：疾患別

• 1型糖尿病
• 2型糖尿病

第10章 市場規模と予測：ブランド別

• 従来型ヒト用インスリンブランド
• 現代型ヒト用インスリンブランド

第11章 市場規模と予測：地域別

• 北米
• 欧州
• アジア太平洋

第12章 糖尿病治療のパイプライン薬

• 開発中の糖尿病治療薬

第13章 競合シナリオ

• 競合ベンチマーキング

第14章 企業プロファイル

• Novo Nordisk A/S
• Eli Lilly and Company
• Sanofi
• Biocon
• Tonghua Dongbao Pharmaceutical Co., Ltd.
• ADOCIA
• Wockhardt
• Julphar
• Merck & Co., Inc
• Pfizer, Inc.
• Bristol-Myers Squibb Company
• GlaxoSmithKline Plc
• Oramed Pharmaceuticals, Inc.

List of Tables

TABLE 1: Market snapshot: Human insulin market, 2022 and 2028

TABLE 2: Drivers for human insulin market: Impact analysis

TABLE 3: Restraints for human insulin market: Impact analysis

TABLE 4: Global human insulin market size, by region, 2014 - 2021 (USD million)

TABLE 5: Global human insulin market size, by region, 2022 - 2028 (USD million)

TABLE 6: Global human insulin market size, by type, 2014 - 2021 (USD million)

TABLE 7: Global human insulin market size, by type, 2022 - 2028 (USD million)

TABLE 8: Global traditional human insulin market size, by region, 2014 - 2021 (USD million)

TABLE 9: Global traditional human insulin market size, by region, 2022 - 2028 (USD million)

TABLE 10: Global modern human insulin market size, by region, 2014 - 2021 (USD million)

TABLE 11: Global modern human insulin market size, by region, 2022 - 2028 (USD million)

TABLE 12: Global short-acting human insulin market size, by region, 2014 - 2021 (USD million)

TABLE 13: Global short-acting human insulin market size, by region, 2022 - 2028 (USD million)

TABLE 14: Global intermediate-acting human insulin market size, by region, 2014 - 2021 (USD million)

TABLE 15: Global intermediate-acting human insulin market size, by region, 2022 - 2028 (USD million)

TABLE 16: Global premixed human insulin market size, by region, 2014 - 2021 (USD million)

TABLE 17: Global premixed human insulin market size, by region, 2022 - 2028 (USD million)

TABLE 18: Global rapid-acting human insulin market size, by region, 2014 - 2021 (USD million)

TABLE 19: Global rapid-acting human insulin market size, by region, 2022 - 2028 (USD million)

TABLE 20: Global long-acting human insulin market size, by region, 2014 - 2021 (USD million)

TABLE 21: Global long-acting human insulin market size, by region, 2022 - 2028 (USD million)

TABLE 22: Global premixed human insulin market size, by region, 2014 - 2021 (USD million)

TABLE 23: Global premixed human insulin market size, by region, 2022 - 2028 (USD million)

TABLE 24: Global type 1 diabetes human insulin market size, by region, 2014 - 2021 (USD million)

TABLE 25: Global type 1 diabetes human insulin market size, by region, 2022 - 2028 (USD million)

TABLE 26: Global type 2 diabetes human insulin market size, by region, 2014 - 2021 (USD million)

TABLE 27: Global type 2 diabetes human insulin market size, by region, 2022 - 2028 (USD million)

TABLE 28: Global traditional human insulin market size, by brand, 2014 - 2021 (USD million)

TABLE 29: Global traditional human insulin market size, by brand, 2022 - 2028 (USD million)

TABLE 30: Global modern human insulin market size, by brand, 2014 - 2021 (USD million)

TABLE 31: Global modern human insulin market size, by brand, 2022 - 2028 (USD million)

TABLE 32: The North American human insulin market size, by country, 2014 - 2021 (USD million)

TABLE 33: The North American human insulin market size, by country, 2022 - 2028 (USD million)

TABLE 34: The U.S. human insulin market size, by type, 2014 - 2021 (USD million)

TABLE 35: The U.S. human insulin market size, by type, 2022 - 2028 (USD million)

TABLE 36: The U.S. traditional human insulin market size, by type, 2014 - 2021 (USD million)

TABLE 37: The U.S. traditional human insulin market size, by type, 2022 - 2028 (USD million)

TABLE 38: The U.S. modern human insulin market size, by type, 2014 - 2021 (USD million)

TABLE 39: The U.S. modern human insulin market size, by type, 2022 - 2028 (USD million)

TABLE 40: The Canadian human insulin market size, by type, 2014 - 2021 (USD million)

TABLE 41: The Canadian human insulin market size, by type, 2022 - 2028 (USD million)

TABLE 42: The Canadian traditional human insulin market size, by type, 2014 - 2021 (USD million)

TABLE 43: The Canadian traditional human insulin market size, by type, 2022 - 2028 (USD million)

TABLE 44: The Canadian modern human insulin market size, by type, 2014 - 2021 (USD million)

TABLE 45: The Canadian modern human insulin market size, by type, 2022 - 2028 (USD million)

TABLE 46: The European human insulin market size, by country, 2014 - 2021 (USD million)

TABLE 47: The European human insulin market size, by country, 2022 - 2028 (USD million)

TABLE 48: The German human insulin market size, by type, 2014 - 2021 (USD million)

TABLE 49: The German human insulin market size, by type, 2022 - 2028 (USD million)

TABLE 50: The German traditional human insulin market size, by type, 2014 - 2021 (USD million)

TABLE 51: The German traditional human insulin market size, by type, 2022 - 2028 (USD million)

TABLE 52: The German modern human insulin market size, by type, 2014 - 2021 (USD million)

TABLE 53: The German modern human insulin market size, by type, 2022 - 2028 (USD million)

TABLE 54: The French human insulin market size, by type, 2014 - 2021 (USD million)

TABLE 55: The French human insulin market size, by type, 2022 - 2028 (USD million)

TABLE 56: The French traditional human insulin market size, by type, 2014 - 2021 (USD million)

TABLE 57: The French traditional human insulin market size, by type, 2022 - 2028 (USD million)

TABLE 58: The French modern human insulin market size, by type, 2014 - 2021 (USD million)

TABLE 59: The French modern human insulin market size, by type, 2022 - 2028 (USD million)

TABLE 60: The U.K. human insulin market size, by type, 2014 - 2021 (USD million)

TABLE 61: The U.K. human insulin market size, by type, 2022 - 2028 (USD million)

TABLE 62: The U.K. traditional human insulin market size, by type, 2014 - 2021 (USD million)

TABLE 63: The U.K. traditional human insulin market size, by type, 2022 - 2028 (USD million)

TABLE 64: The U.K. modern human insulin market size, by type, 2014 - 2021 (USD million)

TABLE 65: The U.K. modern human insulin market size, by type, 2022 - 2028 (USD million)

TABLE 66: The Asia Pacific human insulin market size, by country, 2014 - 2021 (USD million)

TABLE 67: The Asia Pacific human insulin market size, by country, 2022 - 2028 (USD million)

TABLE 68: The Japanese human insulin market size, by type, 2014 - 2021 (USD million)

TABLE 69: The Japanese human insulin market size, by type, 2022 - 2028 (USD million)

TABLE 70: The Japanese traditional human insulin market size, by type, 2014 - 2021 (USD million)

TABLE 71: The Japanese traditional human insulin market size, by type, 2022 - 2028 (USD million)

TABLE 72: The Japanese modern human insulin market size, by type, 2014 - 2021 (USD million)

TABLE 73: The Japanese modern human insulin market size, by type, 2022 - 2028 (USD million)

TABLE 74: The Chinese human insulin market size, by type, 2014 - 2021 (USD million)

TABLE 75: The Chinese human insulin market size, by type, 2022 - 2028 (USD million)

TABLE 76: The Chinese traditional human insulin market size, by type, 2014 - 2021 (USD million)

TABLE 77: The Chinese traditional human insulin market size, by type, 2022 - 2028 (USD million)

TABLE 78: The Chinese modern human insulin market size, by type, 2014 - 2021 (USD million)

TABLE 79: The Chinese modern human insulin market size, by type, 2022 - 2028 (USD million)

TABLE 80: The Indian human insulin market size, by type, 2014 - 2021 (USD million)

TABLE 81: The Indian human insulin market size, by type, 2022 - 2028 (USD million)

TABLE 82: The Indian traditional human insulin market size, by type, 2014 - 2021 (USD million)

TABLE 83: The Indian traditional human insulin market size, by type, 2022 - 2028 (USD million)

TABLE 84: The Indian modern human insulin market size, by type, 2014 - 2021 (USD million)

TABLE 85: The Indian modern human insulin market size, by type, 2022 - 2028 (USD million)

TABLE 86: Major pipeline drugs for diabetes treatment

TABLE 87: Major product segments of Novo Nordisk A/S

TABLE 88: Major product segments of Eli Lilly and Company

TABLE 89: Major product categories of Sanofi

TABLE 90: Major product categories of Biocon

TABLE 91: Major product categories of Tonghua Dongbao Pharmaceutical Co., Ltd.

TABLE 92: Major product categories of Adocia

TABLE 93: Major product categories of Wockhardt

TABLE 94: Major product categories of Julphar

TABLE 95: Major product categories of Merck & Co., Inc.

TABLE 96: Major product categories of Pfizer, Inc.

TABLE 97: Major product categories of Bristol-Myers Squibb Company

TABLE 98: Major product categories of GlaxoSmithKline Plc

TABLE 99: Major product categories of Oramed Pharmaceuticals, Inc.

List of Figures

FIG. 1: Human insulin market: Porter's five forces analysis

FIG. 2: Major types of human insulin

FIG. 3: Major types of insulin delivery devices

FIG. 4: Number of people with diabetes mellitus (20 - 79 years) in major countries, 2010 and 2030 (million)

FIG. 5: Prevalence of overweight and obese males aged 30 years and above, 2022 and 2021 (%)

FIG. 6: Prevalence of overweight and obese females aged 30 years and above, 2022 and 2021 (%)

FIG. 7: Global human insulin market share, by region, by value, 2022

FIG. 8: Global human insulin market share, by type, by value, 2022

FIG. 9: Global traditional human insulin market share, by region, by value, 2022

FIG. 10: Global modern human insulin market share, by region, by value, 2022

FIG. 11: Global short-acting human insulin market share, by region, by value, 2022

FIG. 12: Global intermediate-acting human insulin market share, by region, by value, 2022

FIG. 13: Global premixed human insulin market share, by region, by value, 2022

FIG. 14: Global rapid-acting human insulin market share, by region, by value, 2022

FIG. 15: Global long-acting human insulin market share, by region, by value, 2022

FIG. 16: Global premixed human insulin market share, by region, by value, 2022

FIG. 17: Global type 1 diabetes human insulin market share, by region, by value, 2022

FIG. 18: Global type 2 diabetes human insulin market share, by region, by value, 2022

FIG. 19: Global traditional human insulin market share, by brand, by value, 2022

FIG. 20: Global modern human insulin market share, by brand, by value, 2022

FIG. 21: The North American human insulin market share, by country, by value, 2022

FIG. 22: The U.S. human insulin market share, by type, by value, 2022

FIG. 23: The U.S. traditional human insulin market share, by type, by value, 2022

FIG. 24: The U.S. modern human insulin market share, by type, by value, 2022

FIG. 25: The Canadian human insulin market share, by type, by value, 2022

FIG. 26: The Canadian traditional human insulin market share, by type, by value, 2022

FIG. 27: The Canadian modern human insulin market share, by type, by value, 2022

FIG. 28: The European human insulin market share, by country, by value, 2022

FIG. 29: The German human insulin market share, by type, by value, 2022

FIG. 30: The German traditional human insulin market share, by type, by value, 2022

FIG. 31: The German modern human insulin market share, by type, by value, 2022

FIG. 32: The French human insulin market share, by type, by value, 2022

FIG. 33: The French traditional human insulin market share, by type, by value, 2022

FIG. 34: The French modern human insulin market share, by type, by value, 2022

FIG. 35: The U.K. human insulin market share, by type, by value, 2022

FIG. 36: The U.K. traditional human insulin market share, by type, by value, 2022

FIG. 37: The U.K. modern human insulin market share, by type, by value, 2022

FIG. 38: The Asia Pacific human insulin market share, by country, by value, 2022

FIG. 39: The Japanese human insulin market share, by type, by value, 2022

FIG. 40: The Japanese traditional human insulin market share, by type, by value, 2022

FIG. 41: The Japanese modern human insulin market share, by type, by value, 2022

FIG. 42: The Chinese human insulin market share, by type, by value, 2022

FIG. 43: The Chinese traditional human insulin market share, by type, by value, 2022

FIG. 44: The Chinese modern human insulin market share, by type, by value, 2022

FIG. 45: The Indian human insulin market share, by type, by value, 2022

FIG. 46: The Indian traditional human insulin market share, by type, by value, 2022

FIG. 47: The Indian modern human insulin market share, by type, by value, 2022

FIG. 48: Competitive benchmarking of human insulin manufacturing companies

FIG. 49: Novo Nordisk's net sales and net profit, 2022 - 2028 (USD million)

FIG. 50: Eli Lilly and Company's revenue and net income, 2022 - 2028 (USD million)

FIG. 51: Sanofi's net sales and net income, 2022 - 2028 (USD million)

FIG. 52: Biocon's revenue and profit, 2012 - 2022 (USD million)

FIG. 53: Tonghua Dongbao Pharmaceutical Co., Ltd.'s total revenue and net income, 2022 - 2028 (USD million)

FIG. 54: Wockhardt's revenue and net income, 2022 - 2028 (USD million)

FIG. 55: Julphar's sales and profit, 2022 - 2028 (USD million)

FIG. 56: Merck & Co., Inc.'s sales and net income, 2022 - 2028 (USD million)

FIG. 57: Pfizer, Inc.'s revenue and net income, 2022 - 2028 (USD million)

FIG. 58: Bristol-Myers Squibb Company's total revenue and net earnings, 2022 - 2028 (USD million)

FIG. 59: GlaxoSmithKline Plc's turnover and profit, 2022 - 2028 (USD million)

Human Insulin Market Analysis 2022-2028

A recent market study published by Persistence Market Research (PMR) on the Human Insulin Market including global industry analysis for 2014-2021 & opportunity assessment for 2022-2028, delivers a comprehensive assessment of the most important market dynamics. After conducting a thorough research on the historical as well as current growth parameters of the market, growth prospects are obtained with utmost precision.

Human Insulin Market: Segmentation

The global Human Insulin Market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Type

Modern Human Insulin

Fast-acting

Long-acting

Premix

Traditional Human Insulin

Long-acting

Short-acting

Fast-acting

Premix

Type of Diabetes

Diabetes Type 1

Diabetes Type 2

Distribution Channel

Retail Pharmacies

Hospital Pharmacies

Online Pharmacies

Region

North America

Latin America

Europe

East Asia

South Asia

Oceania

Middle East & Africa (MEA)

Key Questions Answered in Report

The research study offers inclusive insights about the growth of the market in the most comprehensive manner. Key insights offered in the report answer some of the most salient questions that assist stakeholders in gauging all the emerging possibilities.

What are the key trends that are continuously shaping market growth?

Which are the prominent regions that offer plentiful opportunities for players in the market?

How has the outbreak of COVID-19 affected the market and what would the trend be like during the forecast period?

What are the differential strategies adopted by key players to hold a significant share in the human insulin industry?

Research Methodology

A unique and promising research methodology forms the base of the market report for the forecast period. This report has been prepared after comprehensive analysis of market events, and riveting insights have been compiled meticulously.

The research methodology is a two-step process comprising primary and secondary research. Key stakeholders, including suppliers, service providers, and experts of several designations, including executive vice presidents, directors, technical advisors, GM marketing professionals, and sales professionals have been interviewed. Secondary sources referred to obtain information include investor presentations of manufacturers, World Bank, IMF, and other credible sources.

The research report includes a competitive landscape that provides a dashboard view of the key competitors operating in the market. Some of the market players included in this section are Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Biocon, Pfizer Inc, Wockhardt, and Julpha, among others.

Table of Contents

1. Preface

• 1.1. Report Description
• 1.2. Research Methodology
• 1.3. Assumptions

2. Market Synopsis

3. Porter's Five Forces Analysis

• 3.1. Bargaining Power of Suppliers
• 3.2. Bargaining Power of Buyers
• 3.3. Threat of New Entrants
• 3.4. Threat of Substitutes
• 3.5. Intensity of Rivalry

4. Industry Overview

• 4.1. Market Definition
• 4.2. Market Drivers
  • 4.2.1. Growing prevalence of diabetes
  • 4.2.2. Technological advancements in human insulin delivery devices
  • 4.2.3. Increasing awareness among people towards diabetes care
• 4.3. Impact Analysis of Market Drivers
• 4.4. Market Restraints
  • 4.4.1. Uneven pricing and limited access to human insulin in emerging countries
  • 4.4.2. Strict regulatory requirements for drug approval
• 4.5. Impact Analysis of Market Restraints
• 4.6. Market Trends
  • 4.6.1. Increasing usage of insulin pens for administration of human insulin

5. Global Market Size and Forecast

6. Market Size and Forecast by Type

• 6.1. Traditional Human Insulin
• 6.2. Modern Human Insulin

7. Market Size and Forecast of Traditional Human Insulin by Type

• 7.1. Short-acting Human Insulin
• 7.2. Intermediate-acting Human Insulin
• 7.3. Premixed Human Insulin

8. Market Size and Forecast of Modern Human Insulin by Type

• 8.1. Rapid-acting Human Insulin
• 8.2. Long-acting Human Insulin
• 8.3. Premixed Human Insulin

9. Market Size and Forecast by Disease

• 9.1. Type 1 Diabetes
• 9.2. Type 2 Diabetes

10. Market Size and Forecast by Brand

• 10.1. Traditional Human Insulin Brand
• 10.2. Modern Human Insulin Brand

11. Market Size and Forecast by Geography

• 11.1. North America
  • 11.1.1. Scenario in the U.S.
  • 11.1.2. Scenario in Canada
• 11.2. Europe
  • 11.2.1. Scenario in Germany
  • 11.2.2. Scenario in France
  • 11.2.3. Scenario in the U.K.
• 11.3. Asia Pacific
  • 11.3.1. Scenario in Japan
  • 11.3.2. Scenario in China
  • 11.3.3. Scenario in India

12. Pipeline Drugs for Diabetes Treatment

• 12.1. Drugs Under Development for Diabetes Treatment

13. Competitive Scenario

• 13.1. Competitive Benchmarking

14. Company Profiles

• 14.1. Novo Nordisk A/S
  • 14.1.1. Company overview
  • 14.1.2. Products and services
  • 14.1.3. Financial performance
  • 14.1.4. Key developments
• 14.2. Eli Lilly and Company
  • 14.2.1. Company overview
  • 14.2.2. Products and services
  • 14.2.3. Financial performance
  • 14.2.4. Key developments
• 14.3. Sanofi
  • 14.3.1. Company overview
  • 14.3.2. Products and services
  • 14.3.3. Financial performance
  • 14.3.4. Key developments
• 14.4. Biocon
  • 14.4.1. Company overview
  • 14.4.2. Products and services
  • 14.4.3. Financial performance
  • 14.4.4. Key developments
• 14.5. Tonghua Dongbao Pharmaceutical Co., Ltd.
  • 14.5.1. Company overview
  • 14.5.2. Products and services
  • 14.5.3. Financial performance
  • 14.5.4. Key developments
• 14.6. ADOCIA
  • 14.6.1. Company overview
  • 14.6.2. Products and services
  • 14.6.3. Financial performance
  • 14.6.4. Key developments
• 14.7. Wockhardt
  • 14.7.1. Company overview
  • 14.7.2. Products and services
  • 14.7.3. Financial performance
  • 14.7.4. Key developments
• 14.8. Julphar
  • 14.8.1. Company overview
  • 14.8.2. Products and services
  • 14.8.3. Financial performance
  • 14.8.4. Key developments
• 14.9. Merck & Co., Inc.
  • 14.9.1. Company overview
  • 14.9.2. Products and services
  • 14.9.3. Financial performance
  • 14.9.4. Key developments
• 14.10. Pfizer, Inc.
  • 14.10.1. Company overview
  • 14.10.2. Products and services
  • 14.10.3. Financial performance
  • 14.10.4. Key developments
• 14.11. Bristol-Myers Squibb Company
  • 14.11.1. Company overview
  • 14.11.2. Products and services
  • 14.11.3. Financial performance
  • 14.11.4. Key developments
• 14.12. GlaxoSmithKline Plc
  • 14.12.1. Company overview
  • 14.12.2. Products and services
  • 14.12.3. Financial performance
  • 14.12.4. Key developments
• 14.13. Oramed Pharmaceuticals, Inc.
  • 14.13.1. Company overview
  • 14.13.2. Products and services
  • 14.13.3. Financial performance
  • 14.13.4. Key developments